First case of HIV cure reported in a woman after stem cell transplant
The World Health Organization has reported the first case of HIV cure in a woman living with HIV. The woman received a dual stem cell transplant for the treatment of acute myelogenous leukaemia, and has had no detectable HIV levels for 14 months after stopping antiretroviral therapy.
The patient received a transplant of umbilical cord blood stem cells with a CCR5 mutation, as well as a half-matched bone marrow transplant from an adult relative. She was engrafted with 100% cord blood cells at day 100 and had no detectable HIV. The patient stopped antiretroviral therapy at 37 months post transplant.
HIV cure (or remission) has been previously reported in two cases. The first case, known as the Berlin patient (a man with acute myelogenous leukaemia), was reported in 2009. He remained in remission for 12 years, but died of recurrent leukaemia in 2020. The second case, known as the London patient (a man with Hodgkin's lymphoma), was reported in 2019. He has remained in remission for more than 30 months.
This third case of HIV cure suggests that dual stem cell transplant could be considered in people living with HIV who require a stem cell transplant for other diseases. However, the CCR5 mutation is very rare and the chances of finding a suitable stem cell donor are very low.
HIV infection is a pandemic infectious disease whose impact on societies is without precedent.
Globally, an estimated 37.7 million people were living with HIV at the end of 2020, with 1.5 million people newly infected.
Most people are infected through sexual contact, before birth or during delivery, during breastfeeding, or when sharing contaminated needles and syringes.
Diagnosis is established using an HIV antibody test and confirmed using a more specific test. Patients should be clinically staged according to World Health Organization or US Centers for Disease Control and Prevention criteria.
Guidelines recommend that all patients infected with HIV, regardless of CD4 cell count, should start antiretroviral therapy (ART) as soon as possible.
Pre-exposure prophylaxis with daily oral antiretroviral therapy or long-acting intramuscular cabotegravir reduces the risk of HIV infection and is recommended in sexually active adults and people who inject drugs and who are at substantial ongoing risk of HIV exposure and acquisition.
Diagnosis and management varies between resource-intensive settings and resource-limited settings.
HIV infection is caused by a retrovirus that infects and replicates in human lymphocytes and macrophages, eroding the integrity of the human immune system over a number of years, culminating in immune deficiency and a susceptibility to a series of opportunistic and other infections as well as the development of certain malignancies.
At the initial consultation with the medical practitioner, an infected patient may be at any stage of the natural history from acute to chronic infection, ranging from asymptomatic through to severely unwell. The initial assessment is key for prognosis and formulation of short- to long-term management plans.
This topic focuses on the diagnosis and initial management of non-pregnant adults with HIV infection. The management of treatment-experienced patients and special patient populations is beyond the scope of this topic. See Overview of HIV for details of our other topics.
History and exam
Key diagnostic factors
- presence of risk factors
- fevers and night sweats
- weight loss
- skin rashes and post-inflammatory scars
- oral ulcers, angular cheilitis, oral thrush, or oral hairy leukoplakia
- wasting syndrome
- changes in mental status or neuropsychiatric function
- recent hospital admissions
- tuberculosis (TB)
- medical comorbidities
- sexual activity
- generalised lymphadenopathy
- Kaposi's sarcoma
- genital STIs
- chronic vaginal candidiasis
- periodontal disease
- retinal lesions on fundoscopy
- shortness of breath on exertion, cyanosis on exertion, dry cough, silent chest on auscultation
Other diagnostic factors
- current and prior use of other substances
- peripheral neuropathy
- recurrent herpes simplex
- hepatomegaly or splenomegaly
- meningeal signs (bacterial or viral meningitis)
- needle sharing with intravenous drug use
- unprotected receptive anal intercourse
- unprotected receptive penile-vaginal sexual intercourse
- percutaneous needle stick injury
- high maternal viral load (mother to child transmission)
- use of progestin-only injectable contraceptives
- herpes simplex virus type 2 (HSV-2) infection
1st investigations to order
- serum HIV enzyme-linked immunosorbent assay (ELISA)
- serum HIV rapid test
- HIV non-invasive tests
- serum Western blot
- serum p24 antigen
- serum HIV DNA polymerase chain reaction (PCR)
- CD4 count
- serum viral load (HIV RNA)
- drug resistance testing
- pregnancy test
- serum hepatitis B serology
- serum hepatitis C serology
- serum venereal disease research laboratory test
- Treponema pallidum haemagglutination test
- rapid plasma reagin
- tuberculin skin test
- FBC with differential
- serum electrolytes
- serum creatinine
Investigations to consider
- chest x-ray
- liver function tests (LFTs)
- random or fasting lipid profile
- random or fasting plasma glucose
- hepatitis A serology (IgG)
- toxoplasma serology (IgG)
- gonorrhoea and chlamydia testing
- human leukocyte antigen-B*5701 testing
newly confirmed infection
virological or immunological treatment failure
Chad J. Achenbach, MD, MPH
Assistant Professor of Medicine
Feinberg School of Medicine, Northwestern University
CJA has received funds for lecturing at educational events and reimbursement for travel to these lectures by ViiV pharmaceuticals. CJA has been paid for service on a Data Safety Monitoring Board by ABIVAX.
Dr Chad J. Achenbach would like to gratefully acknowledge Dr Richard Rothman, Dr Michael Ehmann, Dr Linda-Gail Bekker, Dr Catherine Orrell, and Dr Lisa Capaldini, the previous contributors to this topic.
ME, LGB, and CO declare that they have no competing interests. RR attended a symposium/conference hosted by a funding agency, Gilead HIV FOCUS programme, from which he receives research funds. RR pays staff for an implementation/research programme grant from Gilead HIV FOCUS for development of HIV testing programmes in Emergency Departments. LC is on the speakers' bureau for the following pharmaceutical companies: GlaxoSmithKline, BMS, Merck, Gilead, Roche, Pfizer, Solvay, Lilly, Serrano, and Tibotec.
Marianne Harris, MD
Clinical Assistant Professor
University of British Columbia
MH is a member of an advisory board and/or speakers' bureau for Gilead Sciences Canada Inc, Merck Canada Inc, and ViiV Healthcare.
William Rodriguez, MD
Assistant Professor of Medicine
Harvard Medical School
Director of Research
Global Health Delivery Project
Harvard School of Public Health
WR declares that he has no competing interests.
Jeremy Day, BChir, MB
Infectious Disease Physician
Oxford University Clinical Research Unit
Hospital for Tropical Diseases
Ho Chi Minh City
JD declares that he has no competing interests.
- Infectious mononucleosis
- Cytomegalovirus infection (CMV)
- Influenza infection
- Guidelines for the use of antiretroviral agents in pediatric HIV infection
- Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV
HIV: what is it?
HIV: testingMore Patient leaflets
Venepuncture and phlebotomy animated demonstrationMore videos
- Log in or subscribe to access all of BMJ Best Practice
Use of this content is subject to our disclaimer